Learning Theater

Interstitial Lung Disease (ILD): From Diagnosis to Decision

Learning Theater 1
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

---

Program Description

Please join expert physician Rohit Gupta, MD, FCCP as he explores a treatment option for adult patients with interstitial lung disease (ILD). Dr. Gupta will review the efficacy and safety data of this treatment option, as well as its use in appropriate patient populations. This presentation is sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

This is a non-CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official CHEST conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST. This promotional presentation is intended for HCP audiences and is based exclusively on information related to JASCAYD’s FDA-approved indication in the United States.

INDICATIONS

JASCAYD is indicated for:

• the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients.
• the treatment of progressive pulmonary fibrosis (PPF) in adult patients.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

• The most common adverse reactions with an incidence of ≥5% in patients treated with JASCAYD were diarrhea, COVID-19, upper respiratory tract infection, depression, weight decreased, decreased appetite, nausea, fatigue, headache, vomiting, back pain, and dizziness.

DRUG INTERACTIONS

Effects of Other Drugs on JASCAYD

• Strong CYP3A Inhibitors: Reduce the dosage of JASCAYD to 9 mg twice daily when used concomitantly with strong CYP3A inhibitors. Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with a strong CYP3A inhibitor increases exposure of nerandomilast, which may increase the risk of JASCAYD adverse reactions.
• Strong or Moderate CYP3A Inducers: Avoid concomitant use of strong CYP3A inducers with JASCAYD. Recommended dosage of JASCAYD is 18 mg twice daily when used concomitantly with moderate CYP3A inducers. Do not reduce the dosage to 9 mg twice daily. Nerandomilast is a CYP3A substrate. Concomitant use of JASCAYD with strong or moderate CYP3A inducers decreases exposure of nerandomilast, which may decrease the efficacy of JASCAYD.
• Pirfenidone: Recommended dosage of JASCAYD is 18 mg twice daily when used concomitantly with pirfenidone. Do not reduce the dosage to 9 mg twice daily. Concomitant use of JASCAYD with pirfenidone decreases exposure of nerandomilast. When JASCAYD was used concomitantly with pirfenidone in patients with IPF in FIBRONEER-IPF, efficacy was not observed with the JASCAYD 9 mg twice daily dosage.

USE IN SPECIFIC POPULATIONS

• Pregnancy: Advise female patients to contact their healthcare provider if they become pregnant or suspect they may be pregnant during treatment with JASCAYD. Advise female patients of the potential risk of fetal loss.
• Lactation: The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for JASCAYD and any potential adverse effects on the breastfed infant from JASCAYD or from the underlying maternal condition.
• Renal Impairment: Use of JASCAYD is not recommended in patients with end stage renal disease (eGFR <15 mL/minute/1.73 m2).
• Hepatic Impairment: Use of JASCAYD is not recommended in patients with severe (Child-Pugh Class C) hepatic impairment.

CL-JS-100020 08.17.2026
(09/26) EM-US-104884

Presenter

Rohit Gupta, MD, FCCP
Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University
Professor
Philadelphia, PA